Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265102 | 0.87 | KDM4E (1.00) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL2267586 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL22744857 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL20203879 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL24616729 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL2268505 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL6631672 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL939060 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL12911394 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 | |
| SCHEMBL2362190 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KDM4ESMN1; SMN2HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116885-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12344615-B2 | Substituted pyridines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12152035-B2 | Androgen receptor binding molecule and use thereof | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2024-11-26 | — | — | US | disclosed |
| WO-2024229221-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-114685601-B | Androgen receptor binding molecules and uses thereof | 财团法人工业技术研究院 | 2024-10-18 | — | — | CN | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344615-B2 | Substituted pyridines as ion channel modulators | SCN1A, CACNA1A, SCN5A | ALDH1A1 819/4885KDM4E 836/4885SMN1; SMN2 147/4885 |
| US-12152035-B2 | Androgen receptor binding molecule and use thereof | AR, SHBG, FSHR | ALDH1A1 2266/4885KDM4E 1913/4885SMN1; SMN2 4854/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | ALDH1A1 3306/4885KDM4E 2441/4885SMN1; SMN2 84/4885 |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | ALDH1A1 2425/4885KDM4E 1462/4885SMN1; SMN2 4443/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | ALDH1A1 916/4885KDM4E 2066/4885SMN1; SMN2 334/4885 |
| US-20260116885-A1 | ION CHANNEL MODULATORS | SCN1B, SCN1A, CACNA1S | ALDH1A1 1251/4885KDM4E 3535/4885SMN1; SMN2 204/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | ALDH1A1 377/4885KDM4E 1039/4885SMN1; SMN2 4314/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | ALDH1A1 806/4885KDM4E 3067/4885SMN1; SMN2 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.